title: Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution.
abstract: Treatment with tyrosine kinase inhibitors (TKIs) has drastically improved overall survival (OS) of patients with advanced GIST. The aim of this study is to evaluate the results of treatment with different TKIs on advanced GIST and identify prognostic factors for OS. The medical records of all patients treated at the Department of Oncology, Aarhus University Hospital were retrospectively reviewed. Between 2001 and 2009, 80 patients with advanced GIST were treated with imatinib as first-line therapy. The median OS was 44 months (95% CI 31-56), and the 5-year OS was 40%. Since 2005, 32 patients were treated with sunitinib as 2nd-line therapy. The median time to progression was 9 months (95% CI: 3-13 months), and the 3-year OS was 30%. The data illustrate that data from large multicenter studies are reproducible in a single sarcoma centre. This retrospective study pointed to low serum sodium at the start of imatinib as a possible prognostic factor affecting OS.
authors.affiliation: Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark.
authors.forename: Ninna
authors.initials: N
authors.lastname: Aggerholm-Pedersen
authors.forename: Peter
authors.initials: P
authors.lastname: Rasmussen
authors.forename: Helle
authors.initials: H
authors.lastname: Dybdahl
authors.forename: Philip
authors.initials: P
authors.lastname: Rossen
authors.forename: Ole Steen
authors.initials: OS
authors.lastname: Nielsen
authors.forename: Akmal
authors.initials: A
authors.lastname: Safwat
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3898-905
references.pmid: 12228211
references.citation: Eur J Cancer. 2011 Mar;47(5):697-701
references.pmid: 21300537
references.citation: J Clin Oncol. 2010 Mar 1;28(7):1247-53
references.pmid: 20124181
references.citation: Lancet. 2006 Oct 14;368(9544):1329-38
references.pmid: 17046465
references.citation: Eur J Cancer. 2005 Aug;41(12):1751-7
references.pmid: 16098458
references.citation: J Clin Oncol. 2005 Aug 20;23(24):5795-804
references.pmid: 16110036
references.citation: Eur J Cancer. 2010 May;46(8):1344-51
references.pmid: 20211560
references.citation: Eur J Cancer. 2006 Sep;42(14):2277-85
references.pmid: 16876399
references.citation: Ann Surg. 2000 Jan;231(1):51-8
references.pmid: 10636102
references.citation: Oncology. 2007;73(3-4):192-7
references.pmid: 18418012
references.citation: Br J Cancer. 2010 Mar 2;102(5):867-72
references.pmid: 20145619
references.citation: Lung Cancer. 2010 Apr;68(1):111-4
references.pmid: 19535164
references.citation: N Engl J Med. 2002 Aug 15;347(7):472-80
references.pmid: 12181401
references.citation: Science. 1998 Jan 23;279(5350):577-80
references.pmid: 9438854
references.citation: Dig Liver Dis. 2008 Nov;40(11):882-9
references.pmid: 18339595
references.citation: Ann Oncol. 2009 May;20 Suppl 4:132-6
references.pmid: 19454434
references.citation: Clin Cancer Res. 2007 Mar 1;13(5):1367-73
references.pmid: 17332278
references.citation: Eur J Cancer. 2003 Sep;39(14):2006-11
references.pmid: 12957454
references.citation: J Clin Oncol. 2008 Feb 1;26(4):620-5
references.pmid: 18235121
references.citation: Cancer. 2005 Feb 15;103(4):821-9
references.pmid: 15648083
references.citation: QJM. 2007 Aug;100(8):501-7
references.pmid: 17609227
references.citation: Cancer. 2000 Jan 1;88(1):66-74
references.pmid: 10618607
references.citation: Invest New Drugs. 2012 Apr;30(2):819-27
references.pmid: 21104107
references.citation: J Clin Oncol. 2008 Feb 1;26(4):626-32
references.pmid: 18235122
references.citation: Eur J Cancer. 2009 Jul;45(11):1959-68
references.pmid: 19282169
references.citation: Br J Surg. 2003 Mar;90(3):332-9
references.pmid: 12594669